ID: ALA3823106

Max Phase: Preclinical

Molecular Formula: C151H232N42O48

Molecular Weight: 3403.76

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCC(NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O

Standard InChI:  InChI=1S/C151H232N42O48/c1-18-22-39-88(173-130(221)91(44-46-113(204)205)174-138(229)102(60-115(208)209)185-145(236)106(68-195)188-134(225)95(52-80-34-25-23-26-35-80)179-144(235)105(67-194)170-112(203)66-165-127(218)101(59-114(206)207)169-111(202)65-164-126(217)85(153)55-83-64-161-69-166-83)128(219)181-100(58-110(157)201)143(234)193-122(79(17)197)150(241)191-120(75(13)21-4)148(239)186-93(50-71(7)8)133(224)184-104(62-117(212)213)140(231)182-98(56-108(155)199)136(227)176-92(49-70(5)6)132(223)168-76(14)124(215)167-77(15)125(216)172-89(42-33-48-162-151(159)160)129(220)183-103(61-116(210)211)139(230)178-96(53-81-36-27-24-28-37-81)142(233)190-119(74(12)20-3)147(238)187-99(57-109(156)200)137(228)180-97(54-82-63-163-86-40-30-29-38-84(82)86)135(226)177-94(51-72(9)10)141(232)189-118(73(11)19-2)146(237)175-90(43-45-107(154)198)131(222)192-121(78(16)196)149(240)171-87(123(158)214)41-31-32-47-152/h23-30,34-38,40,63-64,69-79,85,87-106,118-122,163,194-197H,18-22,31-33,39,41-62,65-68,152-153H2,1-17H3,(H2,154,198)(H2,155,199)(H2,156,200)(H2,157,201)(H2,158,214)(H,161,166)(H,164,217)(H,165,218)(H,167,215)(H,168,223)(H,169,202)(H,170,203)(H,171,240)(H,172,216)(H,173,221)(H,174,229)(H,175,237)(H,176,227)(H,177,226)(H,178,230)(H,179,235)(H,180,228)(H,181,219)(H,182,231)(H,183,220)(H,184,224)(H,185,236)(H,186,239)(H,187,238)(H,188,225)(H,189,232)(H,190,233)(H,191,241)(H,192,222)(H,193,234)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H4,159,160,162)/t73-,74-,75-,76-,77-,78+,79+,85-,87-,88?,89-,90-,91-,92+,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,118-,119-,120-,121-,122-/m0/s1

Standard InChI Key:  DMRADHQGBFFENY-MIAUDGAASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 3403.76

Molecular Weight (Monoisotopic): 3401.7004

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Wiśniewski K, Sueiras-Diaz J, Jiang G, Galyean R, Lu M, Thompson D, Wang YC, Croston G, Posch A, Hargrove DM, Wiśniewska H, Laporte R, Dwyer JJ, Qi S, Srinivasan K, Hartwig J, Ferdyan N, Mares M, Kraus J, Alagarsamy S, Rivière PJ, Schteingart CD..  (2016)  Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.,  59  (7): [PMID:26986178] [10.1021/acs.jmedchem.5b01909]

Source

Source(1):

• Scientific Literature